Tc-99m MAG3
Citation, DOI, disclosures and article data
At the time the article was created Jeremy Jones had no recorded disclosures.
View Jeremy Jones's current disclosuresAt the time the article was last revised Travis Fahrenhorst-Jones had no financial relationships to ineligible companies to disclose.
View Travis Fahrenhorst-Jones's current disclosures- Technetium-99m mercaptoacetyltriglycine (MAG3)
- Technicium-99m MAG3
- Technetium-99m mercaptoacetyltriglycine
- MAG3
Tc-99m MAG3 (mercaptoacetyltriglycine) is one of the technetium radiopharmaceuticals used in renal imaging. Due to favorable energy and dosimetric characteristics, MAG3 radiolabeled with technetium has replaced the iodide-131 Hippuran for the study of renal function (tubular secretion physiology) 7.
Characteristics
photon energy: 140 KeV
physical half-life: 6 hours
biological half-life: 4 hours
technetium oxidation state: +5
normal distribution: kidneys (100%)
-
pharmacokinetics:
uptake by tubular secretion (97%)
first pass filtration 60%
excretion: renal via both glomerular filtration and tubular excretion; hence, in pediatric patients and patients with poor renal function this test is considered superior to DTPA scan
target organ: bladder
-
miscellaneous facts
good quality images with renal insufficiency
by giving captopril, MAG3 plasma clearance decreases in hypertensive patients with renal artery stenosis but increases in patients without renal artery stenosis
cannot measure GFR as it is cleared almost entirely by tubular secretion
during labeling , MAG3 is heated to remove S-benzoyl group. The S-benzoyl group is important to maintain the stability of the compound during storage conditions 8.
ADVERTISEMENT: Supporters see fewer/no ads
Uses, doses and timings
-
renal study
adult dose: 296 MBq (8 mCi) IV
pediatric dose: 3.7 MBq/kg (0.10 mCi/kg) (minimum: 14.8 MBq (0.4 mCi)) 5
60-sec flow study; then every 5 min for 25 min
Quiz questions
References
- 1. Esteves FP, Taylor A, Manatunga A et-al. 99mTc-MAG3 renography: normal values for MAG3 clearance and curve parameters, excretory parameters, and residual urine volume. AJR Am J Roentgenol. 2006;187 (6): W610-7. doi:10.2214/AJR.05.1550 - Pubmed citation
- 2. Vivier PH, Dacher JN. Pharmacokinetics of (99m)Tc-MAG3. AJR Am J Roentgenol. 2009;193 (4): W361. doi:10.2214/AJR.09.2755 - Pubmed citation
- 3. Esteves FP, Halkar RK, Issa MM et-al. Comparison of camera-based 99mTc-MAG3 and 24-hour creatinine clearances for evaluation of kidney function. AJR Am J Roentgenol. 2006;187 (3): W316-9. doi:10.2214/AJR.05.1025 - Pubmed citation
- 4. Müller-Suur R, Tidgren B, Fehrm A et-al. Captopril-induced changes in MAG3 clearance in patients with renal arterial stenosis and the effect of renal angioplasty. J. Nucl. Med. 2000;41 (7): 1203-8. Pubmed citation
- 5. Treves ST, Parisi MT, Gelfand MJ. Pediatric radiopharmaceutical doses: new guidelines. Radiology. 2011;261 (2): 347-9. doi:10.1148/radiol.11110449 - Pubmed citation
- 6. Harvey A. Ziessman, MD, Janis P. O'Malley, MD. Nuclear Medicine: The Requisites. (2013) ISBN: 9780323082990 - Google Books
- 7. Giuliano Mariani, Paola Anna Erba, Duccio Volterrani. Fondamenti di medicina nucleare. (2015) ISBN: 9788847016842
- 8. Technical reports series, No 466. Technetium-99m Radiopharmaceuticals: Manufacture of Kits. 2008. ISBN: 978-92-0-100408-6. International Atomic Energy Agency
Incoming Links
- Renal transplant ultrasound
- Renal imaging in nuclear medicine
- Tc-99m DMSA
- Renal artery stenosis
- Ureteropelvic junction obstruction
- Hydronephrosis
- Perinephric fluid collection post renal transplant
- Medical abbreviations and acronyms (M)
- Technetium-99m agents
- Vesicoureteric reflux
- Cystic renal dysplasia
- Renal transplant scintigraphy
- Pelviureteric junction obstruction and MCDK
- Peripelvic cysts and hydronephrosis
- Vesicoureteric junction obstruction
- Normal dynamic renal scintigraphy
- Polyostotic Paget disease - sternal involvement
- Renal artery stenosis on captopril renal MAG3 nuclear study
- Normal captopril renal MAG3 nuclear study
- Normal renal MAG3 nuclear study
- Pelviureteric obstruction - high-grade
- Normal DMSA scan
- Normal MAG 3
- Crossed fused renal ectopia
- Pelviureteric junction obstruction
Related articles: Imaging technology
- imaging technology
- imaging physics
- imaging in practice
-
x-rays
- x-ray physics
- x-ray in practice
- x-ray production
- x-ray tube
- filters
- automatic exposure control (AEC)
- beam collimators
- grids
- air gap technique
- cassette
- intensifying screen
- x-ray film
- image intensifier
- digital radiography
- digital image
- mammography
- x-ray artifacts
- radiation units
- radiation safety
- radiation detectors
- fluoroscopy
-
computed tomography (CT)
- CT physics
- CT in practice
- CT technology
- CT image reconstruction
- CT image quality
- CT dose
-
CT contrast media
-
iodinated contrast media
- agents
- water soluble
- water insoluble
- vicarious contrast material excretion
- iodinated contrast media adverse reactions
- agents
- non-iodinated contrast media
-
iodinated contrast media
-
CT artifacts
- patient-based artifacts
- physics-based artifacts
- hardware-based artifacts
- ring artifact
- tube arcing
- out of field artifact
- air bubble artifact
- helical and multichannel artifacts
- CT safety
- history of CT
-
MRI
- MRI physics
- MRI in practice
- MRI hardware
- signal processing
-
MRI pulse sequences (basics | abbreviations | parameters)
- T1 weighted image
- T2 weighted image
- proton density weighted image
- chemical exchange saturation transfer
- CSF flow studies
- diffusion weighted imaging (DWI)
- echo-planar pulse sequences
- fat-suppressed imaging sequences
- gradient echo sequences
- inversion recovery sequences
- metal artifact reduction sequence (MARS)
-
perfusion-weighted imaging
- techniques
- derived values
- saturation recovery sequences
- spin echo sequences
- spiral pulse sequences
- susceptibility-weighted imaging (SWI)
- T1 rho
- MR angiography (and venography)
-
MR spectroscopy (MRS)
- 2-hydroxyglutarate peak: resonates at 2.25 ppm
- alanine peak: resonates at 1.48 ppm
- choline peak: resonates at 3.2 ppm
- citrate peak: resonates at 2.6 ppm
- creatine peak: resonates at 3.0 ppm
- functional MRI (fMRI)
- gamma-aminobutyric acid (GABA) peak: resonates at 2.2-2.4 ppm
- glutamine-glutamate peak: resonates at 2.2-2.4 ppm
- Hunter's angle
- lactate peak: resonates at 1.3 ppm
- lipids peak: resonates at 1.3 ppm
- myoinositol peak: resonates at 3.5 ppm
- MR fingerprinting
- N-acetylaspartate (NAA) peak: resonates at 2.0 ppm
- propylene glycol peak: resonates at 1.13 ppm
-
MRI artifacts
- MRI hardware and room shielding
- MRI software
- patient and physiologic motion
- tissue heterogeneity and foreign bodies
- Fourier transform and Nyquist sampling theorem
- MRI contrast agents
- MRI safety
-
ultrasound
- ultrasound physics
-
transducers
- linear array
- convex array
- phased array
- frame averaging (frame persistence)
- ultrasound image resolution
- imaging modes and display
- pulse-echo imaging
- real-time imaging
-
Doppler imaging
- Doppler effect
- color Doppler
- power Doppler
- B flow
- color box
- Doppler angle
- pulse repetition frequency and scale
- wall filter
- color write priority
- packet size (dwell time)
- peak systolic velocity
- end-diastolic velocity
- resistive index
- pulsatility index
- Reynolds number
- panoramic imaging
- compound imaging
- harmonic imaging
- elastography
- scanning modes
- 2D ultrasound
- 3D ultrasound
- 4D ultrasound
- M-mode
-
ultrasound artifacts
- acoustic shadowing
- acoustic enhancement
- beam width artifact
- reverberation artifact
- ring down artifact
- mirror image artifact
- side lobe artifact
- speckle artifact
- speed displacement artifact
- refraction artifact
- multipath artifact
- anisotropy
- electrical interference artifact
- hardware-related artifacts
- Doppler artifacts
- aliasing
- tissue vibration
- spectral broadening
- blooming
- motion (flash) artifact
- twinkling artifact
- acoustic streaming
- biological effects of ultrasound
- history of ultrasound
-
nuclear medicine
- nuclear medicine physics
- detectors
- tissue to background ratio
-
radiopharmaceuticals
- fundamentals of radiopharmaceuticals
- radiopharmaceutical labeling
- radiopharmaceutical production
- nuclear reactor produced radionuclides
- cyclotron produced radionuclides
- radiation detection
- dosimetry
- specific agents
- carbon-11
- chromium-51
- fluorine agents
- gallium agents
- Ga-67 citrate
- Ga-68
- iodine agents
-
I-123
- I-123 iodide
- I-123 ioflupane (DaTSCAN)
- I-123 ortho-iodohippurate
- I-131
-
MIBG scans
- I-123 MIBG
- I-131 MIBG
-
I-123
- indium agents
- In-111 Octreoscan
- In-111 OncoScint
- In-111 Prostascint
- In-111 oxine labeled WBC
- krypton-81m
- nitrogen-13
- oxygen-15
- phosphorus-32
- selenium-75
-
technetium agents
- Tc-99m DMSA
- Tc-99m DTPA
- Tc-99m DTPA aerosol
- Tc-99m HMPAO
- Tc-99m HMPAO labeled WBC
- Tc-99m MAA
- Tc-99m MAG3
- Tc-99m MDP
- Tc-99m mercaptoacetyltriglycine
- Tc-99m pertechnetate
- Tc-99m labeled RBC
- Tc-99m sestamibi
- Tc-99m sulfur colloid
- Tc-99m sulfur colloid (oral)
- thallium-201 chloride
- xenon agents
- in vivo therapeutic agents
- pharmaceuticals used in nuclear medicine
-
emerging methods in medical imaging
- radiography
- phase-contrast imaging
- CT
- deep-learning reconstruction
- photon counting CT
- virtual non-contrast imaging
- ultrasound
- magnetomotive ultrasound (MMUS)
- superb microvascular imaging
- ultrafast Doppler imaging
- ultrasound localization microscopy
- MRI
- nuclear medicine
- total body PET system
- immuno-PET
- miscellaneous
- radiography